221 related articles for article (PubMed ID: 30041662)
1. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.
Genescà E; Lazarenkov A; Morgades M; Berbis G; Ruíz-Xivillé N; Gómez-Marzo P; Ribera J; Juncà J; González-Pérez A; Mercadal S; Guardia R; Artola MT; Moreno MJ; Martínez-López J; Zamora L; Barba P; Gil C; Tormo M; Cladera A; Novo A; Pratcorona M; Nomdedeu J; González-Campos J; Almeida M; Cervera J; Montesinos P; Batlle M; Vives S; Esteve J; Feliu E; Solé F; Orfao A; Ribera JM
J Hematol Oncol; 2018 Jul; 11(1):96. PubMed ID: 30041662
[TBL] [Abstract][Full Text] [Related]
2. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.
Laharanne E; Chevret E; Idrissi Y; Gentil C; Longy M; Ferrer J; Dubus P; Jouary T; Vergier B; Beylot-Barry M; Merlio JP
Mod Pathol; 2010 Apr; 23(4):547-58. PubMed ID: 20118908
[TBL] [Abstract][Full Text] [Related]
5. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
6. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
Iacobucci I; Ferrari A; Lonetti A; Papayannidis C; Paoloni F; Trino S; Storlazzi CT; Ottaviani E; Cattina F; Impera L; Abbenante MC; Vignetti M; Vitale A; Potenza L; Paolini S; Soverini S; Pane F; Luppi M; Foà R; Baccarani M; Martinelli G
Clin Cancer Res; 2011 Dec; 17(23):7413-23. PubMed ID: 22134481
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
[TBL] [Abstract][Full Text] [Related]
9. The Yin and Yang-Like Clinical Implications of the
González-Gil C; Ribera J; Ribera JM; Genescà E
Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33435487
[TBL] [Abstract][Full Text] [Related]
10. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
[TBL] [Abstract][Full Text] [Related]
12. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.
Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D
Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
Pasmant E; Laurendeau I; Héron D; Vidaud M; Vidaud D; Bièche I
Cancer Res; 2007 Apr; 67(8):3963-9. PubMed ID: 17440112
[TBL] [Abstract][Full Text] [Related]
14. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
[TBL] [Abstract][Full Text] [Related]
15. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G
J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
17. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
18. Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish.
Gutierrez A; Feng H; Stevenson K; Neuberg DS; Calzada O; Zhou Y; Langenau DM; Look AT
Br J Haematol; 2014 Jul; 166(1):84-90. PubMed ID: 24690081
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B;
J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Hutter G; Scheubner M; Zimmermann Y; Kalla J; Katzenberger T; Hübler K; Roth S; Hiddemann W; Ott G; Dreyling M
Genes Chromosomes Cancer; 2006 Feb; 45(2):203-10. PubMed ID: 16258956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
